Varian to acquire Cancer Treatment Services International for $283 million

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Posição atual:
>
> This Story

starstarstarstarstar (1)
Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment

 

advertisement

 

Business Affairs Homepage

With stock value up 51 percent, is Mindray too pricey? Valuation has recently soared to $29 billion

Some medical devices exempted from China tariffs Among the recently announced, 110 exemptions

Consumer experience is top priority for 69 percent of US hospitals: survey Trend reflects growing patient burden in paying for services

Noritsu acquires R&F Imaging Systems Expands R&F presence from regional to national scale

Canon hit with $32 million fine by EU for Toshiba deal Used tactic dubbed 'warehousing' to get around filing requirements

Getting to 'yes' in enterprise imaging Tackling common problems on the road to more efficient radiology at SIIM

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

IBM to pay $14.8 million to settle Maryland false claims allegations Settlement revolved around the 2011 acquisition by IBM of Cúram Software

Change Healthcare's IPO now heading beyond $1 billion Offering 49 million shares at $19 each

Silicon Valley investor paints dire picture for future of radiologists Claims they should no longer exist in a decade

Varian acquires Cancer Treatment
Services International

Varian to acquire Cancer Treatment Services International for $283 million

por John R. Fischer , Staff Reporter
Varian Medical Systems is expected to acquire Cancer Treatment Services International (CTSI), offering a sum of $283 million for the privately held enterprise.

The purchase of CTSI provides Varian access to the resources of various organizations and practices operating under it, including the American Oncology Institute in Hyderabad; a U.S.-based Oncology Solutions division that provides cancer care professionals services worldwide; and 10 multidisciplinary cancer centers across the Indian subcontinent.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"The acquisition will put Varian closer to the patient and provider, to gain clinical data and insights critical to enhancing our existing portfolio and expanding into new products and services across the cancer care continuum," Chris Toth, president of Varian Oncology Systems, told HCB News. "This is fully aligned with our strategy and allows us to enter new markets."

With CTSI, Varian will be able to better identify clinical and operational needs that enable the production of the new multidisciplinary solutions, based on robust clinical information that aids oncologists. Early examples of enhanced offerings expected for customers include AI-driven, technology-enabled services for interventional oncology treatment planning, contouring/segmentation, treatment planning as a service in developing markets, and quality assurance services.

It also builds upon the continued growth trajectory of Varian’s oncology systems business and allows the California-based provider and CTSI to expand their solutions to other markets.

"This acquisition enables CTSI to expand the scope and geographic reach of its technology-enabled clinical platform," said Toth. "It will give Varian expertise in cancer center operations, enabling new partnerships with providers globally to expand access to world-class, value-based care in developed and emerging markets, such as China, Southeast Asia, Latin America and Africa."

Having produced annual revenues of $43.5 million in the fiscal years ending in March, the acquisition of CTSI is expected to have a six cents per share dilutive impact to the earnings on a GAAP basis and a three cents per share dilutive impact to earnings on a Non-GAAP basis for the remainder of the fiscal year 2019. Varian expects the acquisition to be accretive to earnings per share during the fiscal years 2021 on a Non-GAAP basis and the fiscal year 2022 on a GAAP basis.

The acquisition will be financed through a combination of borrowings under Varian’s credit facility and cash on hand.

It is expected to close in approximately two weeks, subject to the satisfaction of customary closing conditions.

Employees of CTSI will retain their positions, with the company acting as an operating unit within Varian.

Business Affairs Homepage


You Must Be Logged In To Post A Comment